Journal of Ophthalmic and Optometric Sciences

Vol. 9 No. 3 (2025)

Visual Pathway Dysfunction in Myasthenia Gravis Assessed by Pattern Reversal Visual Evoked Potentials: A Case–Control Study

Journal of Ophthalmic and Optometric Sciences, Vol. 9 No. 3 (2025), 22 Tir 2025 , Page 30-35
https://doi.org/10.22037/joos.v9i3.51182

Abstract

Purpose: To evaluate visual pathway function in individuals with myasthenia gravis using pattern-reversal visual evoked potentials (VEP) and to compare P100 latency and amplitude between affected individuals and healthy controls.
Patients and Methods: A case–control design was used, including 10 individuals with myasthenia gravis (20 eyes) and 10 age-matched healthy controls (20 eyes). Pattern-reversal VEP was recorded monocularly under standardized conditions. P100 latency and amplitudes were measured and statistically compared between groups.
Results: Eyes from the myasthenia gravis group demonstrated significantly prolonged P100 latency (113.1 ± 5.74 ms) compared with controls (98.1 ± 3.33 ms; P < 0.001). P100 amplitude was markedly reduced in the myasthenia gravis group (2.65 ± 1.22 µV) relative to controls (9.00 ± 2.20 µV; P < 0.001).
Conclusion: The results of this study suggest that myasthenia gravis is associated with functional disturbance of the visual pathway, reflected by significant abnormalities in pattern-reversal VEP. Although not diagnostic, VEP may serve as a complementary tool for assessing visual involvement in this condition.

Keywords:
  • Myasthenia Gravis
  • Visual Evoked Potentials
  • Visual Pathways
  • Electrophysiology
  • P100 Component
  • Pattern Reversal Stimulation

How to Cite

Hamzavi, F., Fatemian, N., & Shushtarian, S. M. M. (2025). Visual Pathway Dysfunction in Myasthenia Gravis Assessed by Pattern Reversal Visual Evoked Potentials: A Case–Control Study. Journal of Ophthalmic and Optometric Sciences, 9(3), 30–35. https://doi.org/10.22037/joos.v9i3.51182

References

1- Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012;32(3):215-26.

2- Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020;11:212.

3- Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7-16.

4- Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516.

5- Gilhus NE. Myasthenia gravis, respiratory function, and respiratory tract disease. J Neurol. 2023;270(7):3329-40.

6- Roche P, Bouhour F. Myasthenia gravis and pregnancy. Rev Neurol (Paris). 2021;177(3):215-9.

7- Parrado-Carrillo A, Alcubierre R, Camós-Carreras A, Sanchez-Dalmau BF. Paraneoplastic syndromes in ophthalmology. Arch Soc Esp Oftalmol (Engl Ed). 2022;97(6):350-7.

8- Tutar NK, Ömerhoca S, Söylemez E, Adatepe T, Kale İçen N. The Role of Visual Evoked Potentials in the Differential Diagnosis of Demyelinating Diseases. Turk J Neurol. 2021;27(4): 366-70.

9- Szanyi J, Kremlacek J, Kubova Z, Langrova J, Kuba M. A pilot study to monitor Graves' ophthalmopathy with a combination of pattern-reversal and motion-onset visual evoked potentials. J Clin Apher. 2012;27(6):295-301.

10- Dziadkowiak E, Waliszewska-Prosół M, Wieczorek M, Bladowska J, Budrewicz S, Ejma M. Myasthenia Gravis-An Analysis of Multimodal Evoked Potentials. Brain Sci. 2021;11(8):1057.

11- Fotiou F, Papakostopoulos D, Hamlatzis P. Changes in the pattern reversal visual evoked potentials in myasthenia gravis. Electromyogr Clin Neurophysiol. 1994;34(3):171-5.

12- Mishra AK, Varma A. Myasthenia Gravis: A Systematic Review. Cureus. 2023;15(12):e50017.

  • Abstract Viewed: 23 times
  • pdf Downloaded: 27 times

Download Statastics

Current Issue